ClinicalTrials.gg
Active, not recruitingNCT02713607Updated Feb 10, 2026

Lipidome and Microbiome Profile of Acne

A Phase 1/2 interventional study of Doxycycline in Acne Vulgaris, sponsored by University of California, Davis. Active, not recruiting at 1 site in United States. Open to participants aged 15 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-10.

Sponsored by University of California, Davis · Phase 1/2, Interventional, and Health services research

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
15 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies testing doxycycline in Acne Vulgaris — 2 open to participants now, 3 under way, none of them phase 3. Doxycycline · Acne Vulgaris.

Enrollment
9th of 12
30 · median 47
Started
2016
the only one that year
Phase 1/2
2 of 12
none open now
Registered
8th of 12
by date
Lead sponsor
1 of 12
University of California, Davis

Among the 12 studies testing doxycycline in Acne Vulgaris, this one is the 9th largest by enrollment, is the only one that started in 2016, is one of 2 in phase 1/2, and was the 8th registered.

Acne Vulgaris

795 studies on the registry are indexed under Acne Vulgaris; 96 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

2 of the 12 studies testing doxycycline in Acne Vulgaris are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About doxycycline

Doxycycline: first FDA approval 1967 (VIBRAMYCIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 48 Acne Vulgaris studies recruiting now, 17 (35%) set no upper age limit and 30 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 15 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing doxycycline in Acne Vulgaris, or all of them as a file.
02

Study summary

Lipidome and microbiome analysis in subjects with acne on doxycycline. Investigators will look at the skin lipidome, blood lipidome, gut micro biome and skin micro biome.

Investigators will look at the changes between acne subjects and control participants, but also the changes that occur after the use of antibiotics and how this is altered.

Read the detailed description

We will look at acne subjects, and controls.

We will look at four things

  1. skin lipidome
  2. skin microbiome
  3. gut microbiome
  4. blood lipidome

Investigators will assess this in acne participants before and after doxycycline and compare them to controls.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

04

Who can participate

Ages eligible
15 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 15 and older
  • Subjects/parents/legal guardian is able to read and comprehend study procedure and consent forms.
  • Have already been prescribed Doxycycline by their physician for acne or to be eligible to be prescribed Doxycycline for acne
  • Have acne that is diagnosed by a board certified dermatologist.

Exclusion criteria

Exclusion Criteria:

  • Those who have received systemic antibiotics within four weeks of starting the study.
  • Those who have received systemic isotretinoin within six weeks of starting the study.
  • Those with seborrheic dermatitis, rosacea, or polycystic ovary syndrome
  • Those who are pregnant, prisoners or cognitively impaired.
  • Those subjects who are currently using proton pump inhibits (as studies have shown this may impact the gut microbiome) (4)
  • Those who have a greater than >30 kg/m2, as studies have shown a reduction in the variability of intestinal microbes within this population (5).
  • Those who have initiated or changed brand of oral pill within 4 weeks of starting the study.
  • Those who have disorders as this group has been shown to have an altered microbiome (6)
  • Those who have diabetes (6), immunodeficiencies (7), inflammatory bowel disease (6), hypercholesterolemia, as these groups have been shown to have altered gut microbiomes
  • Those who have taken oral probiotic supplements (8) within 4 weeks of starting the study
  • Given the nature of the instructions that need to be adhered to for accurate collection of samples and this data, non-English speaking individuals will be excluded from this pilot study.
  • Allergies to the tetracycline group of antibiotics
  • Those who do not fit the inclusion criteria
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Health services research
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    doxycycline

    Given doxycycline and assessment of gut, blood and skin

    Drug: Doxycycline

  • No intervention
    Control

    Control subjects to assess if there is baseline difference in these micro-evironments.

Interventions

06

What researchers measure

Primary outcomes

  1. Change in the diversity of the gut microbiome in those with and without acne.

    The diversity will be evaluated by assessing the Bray-Curtis dissimilarity index and the Shannon diversity of the bacterial DNA in the gut microbiome.

    Time frame: 2 years

  2. Change in the diversity of the gut microbiome before and after the treatment of doxycycline in those with acne.

    The diversity will be evaluated by assessing the Bray-Curtis dissimilarity index and the Shannon diversity of the bacterial DNA in the gut microbiome.

    Time frame: 2 years

Secondary outcomes

  1. Change in global acne grade score

    Time frame: 2 years

  2. Change in the investigator global assessment of acne

    Time frame: 2 years

  3. Change in the lesion count of inflammatory and non-inflammatory lesions

    Time frame: 2 years

  4. Change in the diversity of the skin microbiome in those with and without acne

    The diversity will be evaluated by assessing the Bray-Curtis dissimilarity index and the Shannon diversity of the bacterial DNA in the gut microbiome.

    Time frame: 2 years

  5. Change in the diversity of the skin microbiome before and after treatment with doxycycline in those with acne

    The diversity will be evaluated by assessing the Bray-Curtis dissimilarity index and the Shannon diversity of the bacterial DNA in the gut microbiome.

    Time frame: 2 years

  6. Change in the diversity of the skin lipidome in those with and without acne

    The lipid profile will include quantitation of the fatty acid profiles and presence of long chain fatty acids and short chain fatty acids.

    Time frame: 2 years

  7. Change in the skin lipidome before and after treatment with doxycycline in those with acne

    The lipid profile will include quantitation of the fatty acid profiles and presence of long chain fatty acids and short chain fatty acids.

    Time frame: 2 years

  8. Change in the diversity of the blood lipidome in those with and without acne

    The lipid profile will include quantitation of the fatty acid profiles and presence of long chain fatty acids and short chain fatty acids.

    Time frame: 2 year

  9. Change in the blood lipidome before and after treatment with doxycycline in those with

    The lipid profile will include quantitation of the fatty acid profiles and presence of long chain fatty acids and short chain fatty acids.

    Time frame: 2 years

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2016, a primary completion of Jan 2027 and a completion of Jan 2027. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2016
First posted
Mar 21, 2016
Start
Mar 2016
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2027
Last update
Feb 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02713607
Responsible party
Sponsor
First posted
Mar 21, 2016
Start date
Mar 2016
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Feb 10, 2026

Study contacts

Raja K Sivamani, MD MS CAT
principal investigator · UCDavis

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Doxycycline

Start the discussion